MNK Stock - Mallinckrodt plc
Unlock GoAI Insights for MNK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.98B | $198.96M | $2.21B | $2.21B | $2.21B |
| Gross Profit | $827.10M | $136.19M | $891.70M | $891.70M | $669.40M |
| Gross Margin | 41.8% | 68.5% | 40.4% | 40.4% | 30.2% |
| Operating Income | $90.20M | $8.68M | $-1,052,400,000 | $128.60M | $-492,200,000 |
| Net Income | $477.90M | $-11,938,000 | $-717,400,000 | $-723,500,000 | $-969,700,000 |
| Net Margin | 24.1% | -6.0% | -32.5% | -32.8% | -43.8% |
| EPS | $24.26 | $-0.04 | $-4.06 | $-8.54 | $-11.48 |
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland.
Visit WebsiteEarnings History & Surprises
MNKEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2024 | Mar 19, 2024 | — | — | — | — |
Q4 2023 | Dec 18, 2023 | — | — | — | — |
Q3 2023 | Aug 9, 2023 | $1.33 | $1.45 | +9.0% | ✓ BEAT |
Q2 2023 | May 9, 2023 | — | $1.68 | — | — |
Q1 2023 | Feb 28, 2023 | — | $4.07 | — | — |
Q4 2022 | Nov 8, 2022 | — | $5.25 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-2.29 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-1.42 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-2.41 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-3.11 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-1.25 | — | — |
Q2 2021 | May 3, 2021 | — | $-1.70 | — | — |
Q1 2021 | Feb 23, 2021 | — | $-1.81 | — | — |
Q4 2020 | Nov 3, 2020 | $1.33 | $2.26 | +69.9% | ✓ BEAT |
Q3 2020 | Aug 4, 2020 | $1.34 | $1.89 | +41.0% | ✓ BEAT |
Q2 2020 | May 5, 2020 | $1.43 | $1.64 | +14.7% | ✓ BEAT |
Q1 2020 | Feb 25, 2020 | $2.06 | $2.40 | +16.5% | ✓ BEAT |
Q4 2019 | Nov 5, 2019 | $1.97 | $2.07 | +5.1% | ✓ BEAT |
Q3 2019 | Aug 6, 2019 | $2.08 | $2.53 | +21.6% | ✓ BEAT |
Q2 2019 | May 7, 2019 | $1.70 | $1.94 | +14.1% | ✓ BEAT |
Latest News
Frequently Asked Questions about MNK
What is MNK's current stock price?
What is the analyst price target for MNK?
What sector is Mallinckrodt plc in?
What is MNK's market cap?
Does MNK pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MNK for comparison